PREZISTA(R) Now Approved As Part Of Combination Therapy For Pediatric Patients Six Years Of Age And Older With HIV

PREZISTA(R) Now Approved As Part Of Combination Therapy For Pediatric Patients Six Years Of Age And Older With HIV
Tibotec, a division of Janssen-Ortho Inc., announced that Health Canada has approved PREZISTA® (darunavir) for use in children with HIV between the ages of six and 18, dosed twice daily in combination with ritonavir and other antiretroviral agents. PREZISTA® is a protease inhibitor that works by blocking an enzyme critical for the growth of the virus within the body.1 According to the Public …

Read more on Medical News Today